

## FOR IMMEDIATE RELEASE

### **CRITICAL OUTCOME TECHNOLOGIES INC. ANNOUNCES COTI-2 SCIENTIFIC RESULTS ACCEPTED FOR PRESENTATION AT INFLUENTIAL SCIENTIFIC CONFERENCE**

**London, Ontario (October 5, 2011):** Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that a scientific abstract about its lead oncology compound, COTI-2, has been accepted for presentation at the upcoming scientific conference, Discovery on Target: Emerging Targets for the Kinase Inhibitor Pipeline. The presentation entitled *COTI-2: A highly effective and selective modulator of Akt/Akt2 protein levels and phospho-activation for the treatment of susceptible human cancers* will be presented by Dr. Wayne Danter, COTI's CEO and CSO. This conference is being held November 2-4, 2011 in Boston, MA.

"The acceptance of our abstract indicates an eagerness on the part of the oncology community to learn more about our promising COTI-2 program," said Dr. Danter. "This upcoming presentation will afford us the opportunity to showcase to key influencers from many partnering organizations the science behind COTI-2, including the most recent data confirming that Akt/Akt2 are key cellular targets for COTI-2. It also serves as further validation for the ability of our proprietary artificial intelligence system, CHEMSAS®, to generate important drug candidates."

COTI-2 is the most advanced compound in COTI's drug development pipeline and is the first to have been discovered by the CHEMSAS® process. COTI-2's specific cellular targeting, low toxicity, and proven efficacy support a potentially dramatic change in the treatment of cancers that over express Akt/Akt2. Over expression of Akt/Akt2 is common in a broad range of human cancers, including ovarian, endometrial, pancreatic, breast, colorectal and lung. The percent of tumors with active Akt/Akt2 range from 20% to 100% depending on the cancer type.

#### **About Critical Outcome Technologies Inc. (COTI)**

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds most likely to be successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit [www.criticaloutcome.com](http://www.criticaloutcome.com) or contact:

Michael Barr

Vice President of Business Development and Marketing

519-858-5157

[mbarr@criticaloutcome.com](mailto:mbarr@criticaloutcome.com)

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*